Protein– tag –
-
Transcenta Therapeutics and WuXi Biologics Forge Strategic Alliance to Expedite Commercialization of HiCB Continuous Bioprocessing Technologies
BioSpace USA Overview Transcenta Therapeutics and WuXi Biologics have entered a strategic collaboration to accelerate the commercialization and deployment of Transcenta's proprietary High-Intensity Continuous Bioprocessing (HiCB) platfor... -
Integrated Advances in CHO Cell Engineering, Media, Perfusion, and PAT Drive Next-Gen Productivity Leap in Mammalian Cell Culture
Pharma's Almanac USA Overview Volumetric productivity in mammalian cell culture, particularly with CHO cells, has dramatically increased due to integrated advancements in cell engineering, media optimization, high-density seeding, fed-ba... -
US Trade Policy and BIOSECURE Act Drive Major Reshaping and Investment in Global ADC Manufacturing Landscape
Bioprocess Online USA Overview U.S. trade policy and the BIOSECURE Act are significantly reshaping the Antibody-Drug Conjugate (ADC) manufacturing landscape, spurring substantial investments in capacity across the U.S., Europe, and Asia.... -
Ionis’ Zanvastro (Zilganersen) Gains FDA Approval as First Disease-Modifying ASO Therapy for Alexander Disease
Fierce Pharma USA Overview Ionis Pharmaceuticals has received FDA approval for Zanvastro (zilganersen), an antisense oligonucleotide (ASO) therapy, as the first disease-modifying treatment for Alexander disease. Zanvastro operates by spe... -
Catalent Secures $4.1B Refinancing, Fuels Major Expansion in Biologics and Oral Drug Manufacturing to Meet GLP-1 Demand
Pharmaceutical Technology USA Overview Catalent successfully completed a $4.1 billion debt refinancing, earmarking substantial capital for expanding its biologics and oral drug manufacturing capacity. These strategic investments, includi... -
Moderna’s RSV Vaccine mRESVIA® Receives FDA Approval as mRNA Therapeutics Advance in Non-Vaccine Applications
Facebook (Vaxcyte, Vivaldi Biosciences) USA Overview Moderna's RSV vaccine mRESVIA® gained FDA approval following Breakthrough Therapy Designation, reaffirming the power of mRNA technology in infectious disease prevention. Concurrently, ... -
Novartis’ DM1 Therapeutic Delpacibart Etedesiran Fails to Meet Primary Endpoint in Phase III HARBOR Study
Novartis Switzerland Overview Novartis announced that its antibody-oligonucleotide conjugate (AOC) delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1 (DM1) did not achieve a statistically significant improvement in the pr... -
Gan & Lee’s First-in-Class AR PROTAC GLR2037 Receives NMPA Approval to Initiate Clinical Trials for Advanced Prostate Cancer
flcube.com China Overview Gan & Lee Pharmaceuticals announced that China's National Medical Products Administration (NMPA) has approved its first-in-class androgen receptor (AR) PROTAC, GLR2037, for clinical trials. This novel therap... -
First PROTAC Therapy for Breast Cancer Approved, Opening New Avenues for Precision Medicine in Advanced, Metastatic Disease with Specific Mutations
Nature Medicine Journal (Facebook) International Overview A PROTAC therapy for breast cancer has received medical approval, pioneering a new era of precision medicine for patients with advanced or metastatic breast cancer harboring speci... -
Ultragenyx Announces Promising Phase 3 ASPIRE Results for Apazunersen (GTX-102), an ASO Therapeutic for Angelman Syndrome
Ultragenyx Pharmaceutical Inc. USA Overview Ultragenyx has reported promising results from its Phase 3 ASPIRE trial of Apazunersen (GTX-102), an ASO therapeutic for Angelman Syndrome. This drug, one of the first investigational agents ta...
